Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tracking Patient Manifestations of Behçet’s Syndrome around the World

Yusuf Yazici, MD  |  Issue: July 2010  |  July 1, 2010

Since 2005, I have been directing a center for Behçet’s syndrome (BS) at New York University’s (NYU) Hospital for Joint Diseases. One question I am frequently asked is how I got interested in such a rare disease, or at least one that is rare in the U.S. I answer that family history and the Internet played big roles. My father, Hasan Yazici, MD, is also a rheumatologist. He has done a good deal of work on BS and leads one of the largest centers in the world for this disease located in Istanbul, Turkey. When I started practicing, I would get phone calls from patients, mostly from the New York/New Jersey/Connecticut area, who had been diagnosed with BS. Some—but not all—were Turkish. They would say that, while researching BS online, they had found a Dr. Yazici who had done a lot of work with BS, and they would ask if I was that same Dr. Yazici. When I told them I was his son, they would invariably say, “That’s close enough,” and make an appointment to see me.

The Internet and family connection led the first 30 or 40 patients I saw to me. By then, I was working at NYU and thought it would be a good idea to start a center to see if we could better characterize Behçet’s patients in the U.S. To date, we have seen more than 500 patients with Behçet’s, started randomized clinical trials, and worked with the National Institutes of Health to develop further studies. The center has collaborated with neurology, dermatology, and other subspecialties at NYU, and we have worked with our fellows to write abstracts and manuscripts, among other ongoing projects. It has been, and continues to be, a fulfilling experience.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Along the way, we have discovered possible differences between patients with Behçet’s in the U.S. and patients from areas where BS is more endemic. We also have found that this syndrome may not be as rare in the U.S. as was once assumed, especially in the New York area, where the ethnic and racial mix may contribute to the increased incidence of BS.

Figure 1: Virtually all patients with BS have recurrent oral ulcers, such as this one.
Figure 1: Virtually all patients with BS have recurrent oral ulcers, such as this one.

Clinical Features

Behçet’s syndrome is a systemic vasculitis affecting the small and large vessels of both the venous and arterial systems and has an unknown etiology. It was first described by Hulusi Behçet in 1937 on the basis of three patients with a triple-symptom complex of oral aphthae, genital ulcers, and hypopyon uveitis.1 Subsequent studies showed that this entity was a multisystem disease characterized by variable clinical manifestations. Virtually all patients have recurrent oral aphthae (see Figure 1, below), with successively fewer having genital ulcers, skin lesions, arthritis, uveitis, thrombophlebitis, and gastrointestinal (GI) and central nervous system (CNS) involvement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:Behçet’s diseaseDiagnostic CriteriaPathogenesisTreatment

Related Articles

    Case Report: An Unusual Presentation of Neuro-Behçet’s Disease

    April 15, 2022

    A 44-year-old woman presented to the emergency department with bifrontal headaches that had started approximately one month earlier. She was diagnosed with migraines and discharged home. Three days later, the patient returned to the emergency department upon recurrence of her headaches, and this time she also reported abnormal leg movements. A computerized tomography (CT) scan…

    Case Report: A Behçet’s Patient Develops Cerebral Venous Sinus Thrombi

    December 17, 2018

    A 39-year-old woman presented at the emergency department with three weeks of progressive, constant and pulsatile right-sided headache. She said her headache was worse in the morning and when she would bend forward. She reported associated nausea and vomiting. On initial assessment, she did not have any focal neurological deficits. Her medical history was significant for…

    Case Report: Which Vasculitis Is It?

    June 15, 2020

    A 13-year-old, adopted girl of unknown ancestry with social anxiety, selective mutism and Takayasu arteritis presented for evaluation of severe, painful, gingival hyperplasia, which limited her oral intake and resulted in weight loss. The young patient was diagnosed with Takayasu arteritis at age 8, when she presented with a persistently elevated erythrocyte sedimentation rate (ESR),…

    Ustekinumab for Behçet’s Disease? The Study Results Are In

    June 15, 2020

    In a multicenter, prospective, open-label study, ustekinumab therapy was effective in treating oral ulcers resistant to colchicine in patients with Behçet’s disease, according to study author David Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology, Sorbonne University, Paris, and fellow researchers.1 Researchers focused on the topic because oral ulcers are often disabling, have…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences